Morgan Stanley Lowers Novo Nordisk Rating to Underweight and Reduces Price Target from $59 to $47
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 29 2025
0mins
Source: Yahoo Finance
- Stock Rating: Novo Nordisk (NVO) has an average rating of overweight.
- Price Target: The mean price target for Novo Nordisk is set at $70.25.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
